In September 2016, Paul Cahill settled a medical malpractice claim on behalf of a 57-year-old woman who suffered permanent vestibular damage during two weeks of outpatient intravenous gentamicin therapy. The patient had presented to an Ontario emergency department with pyelonephritis, a serious kidney infection that requires aggressive antibiotic treatment. Because she had documented allergies to several first-line antibiotics, gentamicin was selected. She was discharged from the hospital to receive her daily intravenous doses in the community over approximately the next two weeks. During that two-week period, she received the antibiotic. She did not receive the monitoring that was supposed to accompany it. By the time the course was complete, she had developed severe and irreversible vestibular toxicity. She was left significantly disabled.
Gentamicin is one of the most clinically useful antibiotics in the modern formulary. It is also one of the most carefully monitored. The medical literature on aminoglycoside ototoxicity is extensive and well-established. The monitoring protocols required to deliver gentamicin safely are not technically demanding. They consist principally of regular blood tests, regular checks of kidney function, and routine inquiry into a small set of clinical symptoms that, if reported, dictate immediate discontinuation of the drug. When those protocols are followed, the rate of permanent vestibular toxicity is low. When they are not followed, the rate is materially higher, and the outcome can be the kind of permanent functional disability this case produced.
The civil claim was advanced against the treating physicians and the hospital that arranged for the outpatient antibiotic delivery. The settlement was reached without admission of liability and the terms are confidential. The clinical and legal pattern, however, is one that bears explaining. Community-administered intravenous antibiotic therapy, sometimes called outpatient parenteral antimicrobial therapy or OPAT, is increasingly common in Ontario, and the duty to monitor remains with the prescriber even when the daily administration is performed by community nursing services or at infusion centres.
The clinical context
Gentamicin is an aminoglycoside antibiotic. The aminoglycoside class includes streptomycin, tobramycin, amikacin, and several other agents, and has been in clinical use since the 1940s. The drugs are bactericidal, meaning they kill bacteria outright rather than slowing their growth, and they are particularly effective against gram-negative organisms, including the Escherichia coli and Klebsiella species that are the most common causes of pyelonephritis. They are also among the cheapest and most widely available antibiotics in the world. For severe infections in patients with allergies to first-line agents such as the penicillins and the cephalosporins, gentamicin remains a clinically important option.
The class also has well-known toxicities. The two most significant are nephrotoxicity, meaning damage to the kidneys, and ototoxicity, meaning damage to the inner ear. The ototoxicity has two forms. Cochlear toxicity affects hearing and typically produces high-frequency sensorineural hearing loss and tinnitus. Vestibular toxicity affects the balance organs and produces a constellation of symptoms that includes imbalance, oscillopsia (the perception that the visual world bounces with head movement), persistent nausea, ataxia (uncoordinated walking), and a profound inability to maintain balance with the eyes closed or in the dark. Different aminoglycosides have different toxicity profiles. Streptomycin and tobramycin are primarily vestibulotoxic. Amikacin and neomycin are primarily cochleotoxic. Gentamicin sits in between, but the published literature treats it as primarily vestibulotoxic, with vestibular symptoms accounting for roughly two-thirds of ototoxic adverse events.
Once it occurs, vestibular toxicity from gentamicin is often irreversible. The mechanism is destruction of the hair cells of the vestibular sensory epithelium. Some recovery is possible if the drug is discontinued early, but established damage tends not to repair. Patients with bilateral vestibular hypofunction following gentamicin describe a particular functional impairment: they cannot walk in the dark, they cannot stand on a soft surface without falling, they cannot drive safely, and they cannot turn their head while reading because the visual world ceases to be stable. Many have permanent oscillopsia. The disability is severe, persistent, and, in most cases, life-altering.
The standard for monitoring
Because gentamicin toxicity is well-recognized and largely preventable, the clinical guidance for monitoring patients on the drug is detailed and well-established. The practice guidelines of the Infectious Diseases Society of America for outpatient parenteral antimicrobial therapy, and the related United Kingdom guidance from the British Society for Antimicrobial Chemotherapy, both call for specific safeguards when an aminoglycoside is delivered in an outpatient setting. Those safeguards include the following.
Therapeutic drug monitoring. Aminoglycosides have a narrow therapeutic index. The published guidelines call for serum drug levels to be measured regularly during outpatient therapy, including trough levels drawn immediately before a scheduled dose and, in some protocols, peak levels drawn shortly after dose completion. The results inform dose adjustment. Sustained elevated trough levels are associated with toxicity and require dose reduction or discontinuation.
Renal function monitoring. Aminoglycosides are eliminated by the kidneys, and impaired renal function leads to drug accumulation and elevated toxicity risk. The guidelines call for weekly serum creatinine measurements during outpatient therapy, with more frequent monitoring in patients at higher renal risk. A rising creatinine is itself a signal to reconsider the therapy.
Daily symptom inquiry. The single most important safeguard against established vestibular toxicity is early recognition of vestibular symptoms and prompt discontinuation. The published research, including the systematic vestibular monitoring protocols developed for patients on prolonged aminoglycoside therapy for endocarditis and other indications, calls for daily inquiry about imbalance, dizziness, oscillopsia, nausea, and any new gait difficulty. Even brief or vague reports of these symptoms during aminoglycoside therapy are treated as a signal to stop the drug, perform bedside vestibular testing, and obtain a neurotological evaluation. Continuing the drug after such symptoms have been reported is associated with progression from reversible to permanent injury.
Audiometry and bedside vestibular testing where indicated. The published guidance includes baseline and follow-up audiometry, and, for patients on prolonged courses, periodic bedside vestibular testing such as the video head impulse test. These investigations can identify subclinical injury before the patient develops symptoms severe enough to disable them.
The structure of these safeguards reflects two clinical realities. The first is that aminoglycoside vestibular toxicity is not always preceded by warning signs the patient knows to volunteer. Symptoms can be insidious, vague, or initially dismissed as related to the underlying infection. The second is that the window between reversible and irreversible injury is short. The standard of care places the responsibility for identifying that window on the prescriber, not on the patient.
The patient and the gap in monitoring
The patient was 57 years old. She presented to an Ontario emergency department with pyelonephritis. Because she had documented allergies to multiple antibiotics typically used to treat upper urinary tract infections, the treating physicians selected gentamicin. The drug is a defensible clinical choice for a patient with relevant allergies. The decision to deliver the drug in the community rather than admitting the patient for inpatient therapy is also a defensible clinical choice. Outpatient parenteral antimicrobial therapy is well-established in Ontario practice and is appropriate for many patients with serious infections who are otherwise stable.
What the decision to deliver gentamicin in the community does not do is reduce the monitoring obligation. The monitoring obligation, if anything, increases in the outpatient setting. When a patient is in hospital, they are seen daily by nursing and medical staff, their laboratory results are reviewed automatically, and any change in their condition is documented and communicated. When the same patient is at home receiving the same drug via a community nursing service, the structured oversight is lost. The published literature on OPAT is explicit that the prescribing physician retains the obligation to monitor and that the monitoring must be planned, documented, and acted upon.
In the patient’s case, the monitoring that the standard of care required did not occur. Over the approximately two-week course of daily intravenous gentamicin, the patient was not seen for clinical reassessment in any structured way. The blood work that would have detected drug accumulation or rising creatinine was not ordered. The daily symptom inquiry that would have caught the earliest signs of vestibular involvement was not performed. By the time the course was complete, the patient had developed bilateral vestibular hypofunction. The damage was permanent. She was left significantly disabled.
The legal framework
A claim of this kind sits in a category of medication-monitoring negligence that has a recognizable analytical structure. The general elements of a civil malpractice claim are explained in our foundational post on suing for medical malpractice in Ontario. Their application to a case involving an aminoglycoside and a failure of outpatient monitoring is as follows.
Standard of care. The standard of care for prescribing aminoglycosides, both at the time of this case and today, requires that the prescribing physician, or a delegated team operating under the prescribing physician’s responsibility, establish a monitoring plan before the patient begins the drug, document that plan, and ensure that it is followed. The plan must address therapeutic drug monitoring, renal function monitoring, and daily clinical symptom inquiry. When the drug is delivered in the community rather than in hospital, the plan must include arrangements for the community team to communicate clinical observations and laboratory results back to the prescribing physician, and for the prescribing physician to review them and act on them. The plan does not need to be elaborate. It needs to exist, to be documented, and to be followed.
A failure to establish a monitoring plan, or a failure to act on the information the plan generates, is a recognized breach of the standard of care. The published guidance is clear, the published literature is extensive, and the expert evidence in cases of this kind is well-developed.
Causation. Causation in aminoglycoside ototoxicity is supported by well-established dose-response and time-response relationships in the published literature. Cumulative dose, duration of therapy, sustained elevated serum levels, and impaired renal function all increase the risk of permanent vestibular injury. Where the patient has received a sustained course of an aminoglycoside without monitoring and has subsequently developed bilateral vestibular hypofunction, the causal link between the breach and the injury is supported by the medical evidence. The defence in such cases sometimes argues that the patient’s vestibular symptoms preceded the gentamicin or were caused by an unrelated condition, but those arguments are typically not strong where the clinical pattern, the timeline, and the physical findings are consistent with aminoglycoside vestibulopathy.
Damages. Bilateral vestibular hypofunction is a deeply disabling condition. Patients experience ongoing imbalance, oscillopsia, falls, an inability to work in any occupation requiring movement or rapid head changes, an inability to drive, and significant restrictions on their participation in everyday activities. The condition is permanent. The damages in a case of this kind typically include general damages for pain and suffering and loss of enjoyment of life, lost past and future income, the cost of past and future care including any necessary mobility aids or home modifications, and the cost of vestibular rehabilitation. For a working-age patient like the plaintiff in this case, the future-income and future-care components are substantial.
How the case resolved
The matter settled on confidential terms before trial. The factors that supported a productive negotiation included clear expert evidence on the standard of care for monitoring outpatient aminoglycoside therapy, expert evidence on the causal link between the unmonitored two-week course and the patient’s bilateral vestibular injury, and significant documented damages.
Why this case matters
For patients receiving intravenous antibiotics in the community, the lesson of this case is to ask, explicitly, what the monitoring plan is. The questions a patient and family are entitled to put to the prescribing physician include: How often will my blood be drawn during this course? What levels are you looking for? What symptoms should I report and to whom? Who is checking my creatinine and my drug levels, and how often? If I develop dizziness, ringing in my ears, or trouble with my balance, what should I do? The answers should be specific. A patient on an aminoglycoside whose physician cannot articulate a monitoring plan is a patient whose monitoring may not be happening.
For physicians prescribing aminoglycosides, the lesson is that the published guidance describes a standard of care that the courts will apply. The plan must exist. The plan must be communicated to the patient, to the community team, and to the prescribing physician’s own records. The plan must include therapeutic drug monitoring, renal function monitoring, and daily symptom inquiry. The plan must be followed. None of these elements is technically demanding. Their absence, however, is what aminoglycoside-toxicity litigation tends to expose.
For hospitals and outpatient antibiotic programs, the lesson is that the institutional infrastructure for OPAT must include monitoring as a designed feature, not as a discretionary add-on. Where the hospital arranges community delivery of a drug with the toxicity profile of gentamicin, the hospital’s clinical pathways must specify who is responsible for the monitoring, how the monitoring information will be communicated and reviewed, and how a clinical concern will be escalated. The absence of such a pathway, as the published literature on OPAT consistently emphasizes, is associated with higher rates of preventable harm.
For the broader practice of medical malpractice litigation in Ontario, this case sits in the category of medication-monitoring failures, which is doctrinally distinct from prescription errors or administration errors. The breach is not in the choice of drug or in the way it was delivered. The breach is in what did not happen alongside the delivery: the laboratory tests that were not ordered, the symptom inquiry that was not performed, the clinical reassessment that did not occur, the discontinuation decision that was therefore never made. This category of breach is recognizable across multiple drug classes (warfarin, lithium, methotrexate, clozapine, and several others), and the analytical structure of an aminoglycoside case applies, with appropriate adjustments, to each.
Settlement Date: September 2016
Jurisdiction: Ontario
Counsel for the plaintiff: Paul J. Cahill
